Papers/PMID:41401723
Sodium benzoate treatment linked to increased glutathione levels and improved positive and negative symptoms, global function, and quality of life in patients with clozapine-resistant schizophrenia: secondary analysis of a randomized clinical trial.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2026The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
sodium benzoate — increases reduced glutathione concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“As a result, six-week treatment of sodium benzoate was linked to increased GSH levels than placebo.”
Quoted verbatim from Sodium benzoate treatment linked to increased glutathione levels and improved positive and negative symptoms, global function, and quality of life in patients with clozapine-resistant schizophrenia: secondary analysis of a randomized clinical trial.. - Study
- RCT
- Duration
- 6 weeks
- Population
- Patients with clozapine-resistant schizophrenia on add-on treatment; plasma GSH, baseline to endpoint
Sodium benzoate treatment linked to increased glutathione levels and improved positive and negative symptoms, global function, and quality of life in patients with clozapine-resistant schizophrenia: secondary analysis of a randomized clinical trial.2026PMID:41401723Permalink